

Graphene Oxide/ZnS:Mn Nanocomposite Functionalized with Folic Acid as a Nontoxic and Effective Theranostic Platform for Breast Cancer Treatment

Daysi Diaz-Diestra ^{1,2,*}, Bibek Thapa ^{1,4}, Dayra Badillo-Diaz ⁵, Juan Beltran-Huarac ^{3,*}, Gerardo Morell ^{1,4} and Brad R. Weiner ^{1,2}

¹ Molecular Sciences Research Center, University of Puerto Rico, San Juan, PR 00926, USA; bibeck.thapa@gmail.com (B.T.); gerardo.morell@upr.edu (G.M.); bradrweiner@gmail.com (B.R.W.)

² Department of Chemistry, University of Puerto Rico, San Juan, PR 00925-2537, USA

³ Department of Environmental Health, Center for Nanotechnology and Nanotoxicology, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA

⁴ Department of Physics, University of Puerto Rico, San Juan, PR 00925-2537, USA

⁵ Department of Biology, University of Puerto Rico, San Juan, PR 00925-2537, USA; dnbd1118@hotmail.com

* Correspondence: daysi.diaz@upr.edu (D.D.-D.); juanbh@email.unc.edu (J.B.-H.)




Figure S1. PL spectra of FA-rGO/ZnS:Mn and rGO/ZnS:Mn under 325 nm light excitation.




Figure S2. (A) Zeta potential of FA-rGO/ZnS:Mn and rGO/ZnS:Mn in PBS (pH 7.4) and cellular media supplemented with FBS. (B) Mean hydrodynamic size of FA-rGO/ZnS:Mn dispersed in both DMEM and DMEM supplemented with FBS at 0 and 24 hrs.




Figure S3. (A) *In-vitro* MTS cell viability and (B) LDH release of MDA-MB 231 cells when exposed to FA-rGO/ZnS:Mn and rGO/ZnS:Mn (which are dispersed through ultrasonication-U and bath sonication-B) at different doses for 24 hrs of incubation.